NASDAQ:SLNOSoleno Therapeutics Stock Price, Forecast & News

Soleno Therapeutics' stock was trading at $2.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SLNO stock has increased by 59.4% and is now trading at $4.00. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Soleno Therapeutics.

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Soleno Therapeutics.

Soleno Therapeutics Inc (NASDAQ:SLNO) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.07. View Soleno Therapeutics' earnings history.

Shares of Soleno Therapeutics reverse split on the morning of Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

3 brokerages have issued twelve-month price targets for Soleno Therapeutics' stock. Their forecasts range from $8.00 to $10.00. On average, they anticipate Soleno Therapeutics' share price to reach $9.33 in the next twelve months. This suggests a possible upside of 133.3% from the stock's current price. View analysts' price targets for Soleno Therapeutics.

News stories about SLNO stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Soleno Therapeutics earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutSoleno Therapeutics.

Soleno Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 143,100 shares, an increase of 44.7% from the April 30th total of 98,900 shares. Based on an average daily trading volume, of 125,700 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.6% of the company's shares are short sold. View Soleno Therapeutics' Current Options Chain.

Some companies that are related to Soleno Therapeutics include Natus Medical (NTUS), Zynex (ZYXI), TransMedics Group (TMDX), BioLife Solutions (BLFS), AxoGen (AXGN), BioSig Technologies (BSGM), Stereotaxis (STXS), Semler Scientific (SMLR), Viewray (VRAY), Cutera (CUTR), Fonar (FONR), Edap Tms (EDAP), Fc Global Realty (FCRE), electroCore (ECOR) and IRIDEX (IRIX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include SCYNEXIS (SCYX), Anavex Life Sciences (AVXL), Molecular Templates (MTEM), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Opko Health (OPK), Sorrento Therapeutics (SRNE), Tetraphase Pharmaceuticals (TTPH), AVEO Pharmaceuticals (AVEO) and Dynavax Technologies (DVAX).

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Soleno Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vivo Capital LLC (4.52%), Geode Capital Management LLC (0.31%), BlackRock Inc. (0.19%), Oppenheimer & Co. Inc. (0.13%), Squarepoint Ops LLC (0.09%) and AE Wealth Management LLC (0.02%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Bioasia Mangement Llc, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Technology Partners Fund Vii L, Ventures Fund V LP Vivo and Vivo Ventures V, Llc. View institutional ownership trends for Soleno Therapeutics.

SLNO stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Geode Capital Management LLC, Oppenheimer & Co. Inc., Squarepoint Ops LLC, BlackRock Inc., and AE Wealth Management LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler, and Larry N Feinberg. View insider buying and selling activity for Soleno Therapeutics.

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SLNO stock can currently be purchased for approximately $4.00.

Soleno Therapeutics has a market capitalization of $178.84 million. The company earns $-30,770,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.

The official website for Soleno Therapeutics is www.soleno.life.

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]